SCHEMBL504189

SCHEMBL504189

N#CCCCCCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.60
LMNA P02545 2/20 0.60
HSD17B10 Q99714 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
MAPT P10636 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
NFKB1 P19838 1/20 0.60
PMP22 Q01453 1/20 0.60
PTPN7 P35236 3/20 0.54
HMGCR P04035 3/20 0.54
GPR84 Q9NQS5 4/20 0.50
FFAR1 O14842 2/20 0.50
FFAR4 Q5NUL3 2/20 0.50
PPARG P37231 5/20 0.48
PPARD Q03181 5/20 0.48
PPARA Q07869 5/20 0.48
HDAC11 Q96DB2 4/20 0.48
ALDH1A1 P00352 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609292 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL3761638 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL4188688 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL9351053 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL1285460 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL9352237 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL2210214 1.00 TSHR (0.60) TSHRLMNAHSD17B10CYP1A2CYP2D6
Ammonia Solution, Strong SCHEMBL5979550 0.98 HSD17B10 (0.58) TSHRLMNAHSD17B10CYP1A2CYP2D6
SCHEMBL454017 0.97
Adipic Acid SCHEMBL9504707 0.97 LMNA (0.58) TSHRLMNAHSD17B10CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117393768-B Positive electrode material for sodium ion battery, preparation method of positive electrode material and sodium ion battery 天鹏锂能技术(淮安)有限公司 2024-08-27 CN claimed
CN-117393768-A Positive electrode material for sodium ion battery, preparation method of positive electrode material and sodium ion battery 天鹏锂能技术(淮安)有限公司 2024-01-12 CN claimed
CN-117080450-B Positive pole piece of sodium ion battery and sodium ion battery 江苏天鹏电源有限公司 2023-12-26 CN claimed
CN-117080450-A Positive pole piece of sodium ion battery and sodium ion battery 江苏天鹏电源有限公司 2023-11-17 CN claimed
CN-117393768-B Positive electrode material for sodium ion battery, preparation method of positive electrode material and sodium ion battery 天鹏锂能技术(淮安)有限公司 2024-08-27 CN disclosed
US-12037463-B2 Antimicrobial ophthalmic devices comprising polysiloxane-polyglycerol block copolymers and methods of making and use thereof Clearlab Sg Pte Ltd. (SG) 2024-07-16 US disclosed
US-12024597-B2 Wound dressings comprising polysiloxane-polyglycerol block copolymers and methods of making and use thereof Clearlab Sg Pte Ltd. (SG) 2024-07-02 US disclosed
CN-117393768-A Positive electrode material for sodium ion battery, preparation method of positive electrode material and sodium ion battery 天鹏锂能技术(淮安)有限公司 2024-01-12 CN disclosed
CN-117080450-B Positive pole piece of sodium ion battery and sodium ion battery 江苏天鹏电源有限公司 2023-12-26 CN disclosed
CN-117080450-A Positive pole piece of sodium ion battery and sodium ion battery 江苏天鹏电源有限公司 2023-11-17 CN disclosed
WO-2023184791-A1 METHOD FOR ENZYMATIC SYNTHESIS OF BRIVARACETAM CHIRAL INTERMEDIATE 浙江工业大学 2023-10-05 WO disclosed
US-20230227613-A1 ANTIMICROBIAL OPHTHALMIC DEVICES COMPRISING POLYSILOXANE-POLYGLYCEROL BLOCK COPOLYMERS AND METHODS OF MAKING AND USE THEREOF CLEARLAB SG PTE LTD (SG) 2023-07-20 US disclosed
US-20030212290-A1 Asymmetric synthesis of pregabalin BURK MARK JOSEPH (US) 2003-11-13 US disclosed
EP-1250311-A1 ASYMMETRIC SYNTHESIS OF PREGABALIN WARNER-LAMBERT COMPANY (US) 2002-10-23 EP disclosed
WO-2001055090-A1 ASYMMETRIC SYNTHESIS OF PREGABALIN WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed
EP-0730574-B1 PROCESSES AND CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS DU PONT (US) 1998-08-19 EP disclosed
US-5723641-A PHOSPHITE CATALYSTS FOR HYDROCYANATION E. I. DU PONT DE NEMOURS AND COMPANY (US) 1998-03-03 US disclosed
US-5688986-A CATALYTIC HYDROCYANATION OF NONCONJUGATED ACYCLIC ALIPHATIC MONOOLEFIN, MONOOLEFIN CONJUGATED TO ESTER OR MONOOLEFIN CONJUGATED TO CYANIDE IN THE PRESENCE OF NICKEL PHOSPHITE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1997-11-18 US disclosed
EP-0730574-A1 PROCESSES AND CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-09-11 EP disclosed
WO-1995014659-A1 PROCESSES AND CATALYST COMPOSITIONS FOR HYDROCYANATION OF MONOOLEFINS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1995-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212290-A1 Asymmetric synthesis of pregabalin GABRA5, GABRA6, GABRE TSHR 4184/4885LMNA 4428/4885HSD17B10 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.